A resolution expressing the sense of the Senate that the Department of Justice should reverse its position in Texas v. United States, No. 4:18-cv-00167-O (N.D. Tex.).

H.R.1897 MOMMA's Act - Federal efforts with respect to the prevention of maternal mortality H.R.2115 Public Disclosure of Drug Discounts Act - legislation to provide greater transparency of discounts provided by drug manufacturers. S.340/H.R.965 CREATES - facilitate the timely entry of lower-cost generic and biosimilar versions of drugs and biological products H.R. 938 the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019 - eligibility for FDA approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval H.R. 1520, the Purple Book Continuity Act of 2019; publication of a list of licensed biological products H.R. 1503, the Orange Book Transparency Act of 2019; list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, H.R. 1781 Payment Commission Data Act of 2019 - provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information H.R. 1264 Payment Commission Data Act of 2019 - provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019 - pay for delay; prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products H.R.2113 Prescription Drug STAR Act - require drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, H.R.2296, S.1391 FAIR Drug Pricing Act - Rx pricing transparency, require manufacturers to justify price increases H.R.2376, S.1227 Prescription Pricing for the People Act - directs the Federal Trade Commission to report to Congress on the effect of certain anticompetitive practices in the pharmaceutical supply chain S.Res.134 - A resolution expressing the sense of the Senate that the Department of Justice should reverse its position in Texas v. United States, No. 4:18-cv-00167-O (N.D. Tex.) H.R.1010 - To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect H.Res.356 - Expressing support for Designation of May as "National Asthma and Allergy Awareness Month" H.R.1868 - Health Care Affordability Act of 2019 - reducing insurance premiums and out-of-pocket costs in the individual and small group markets, both for low-income families and those that are not eligible for tax credits H.R.1385 State Allowance for a Variety of Exchanges (SAVE) Act - preserve the option of States to implement health care marketplaces H.R.1386 ENROLL Act - amending ACA with new Navigator program requirements H.R.1425 State Health Care Premium Reduction Act - Improve Health Insurance Affordability Fund to provide for certain reinsurance payments to lower premiums in the individual health insurance market S.1213 Consumer Health Insurance Protection Act - - comprehensive insurance reform proposals including provisions pegging consumer assistance to plans with higher actuarial value, lowering out-of-pocket maximums, extending eligibility for subsidies, fixing family glitch, investing in enrollment outreach, requiring insurers to cover emergency services at in-network costs, making short-term limited duration plans subject to ACAs consumer protections H.R.986 - Protecting Americans with Preexisting Conditions Act of 2019 - certain guidance related to waivers for State innovation under the Patient Protection and Affordable Care Act shall have no force or effect H.R.2569, S.1365 Comprehensive Addiction Resources Emergency Act of 2019 - provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families H.R.987 Strengthening Health Care and Lowering Prescription Drug Costs Ac- requires the Department of Health and Human Services (HHS) to conduct outreach and educational activities regarding federally-facilitated exchanges (i.e., health insurance exchanges that are established and operated within states by HHS). The activities must inform potential enrollees of the availability of coverage and related financial assistance under the exchanges and must be provided in culturally and linguistically appropriate formats. S.1556 No Junk Plans Act - rule entitled Short-Term, Limited Duration Insurance shall have no force or effect. S.1531 STOP Surprise Medical Bills Act - provide protections for health insurance consumers from surprise billing H.R.861 - End Surprise Billing Act of 2019 - prevent surprise billing practices and require notification for consumers Lower Health Care Costs Act - comprehensive legislation to end surprise medical bills, reduce prescription drug prices, improve health care transparency, improve public health, improve exchange of health information No Surprises Act - legislation to protect consumers from surprise medical bills Protecting People From Surprise Medical Bills Act - legislation to protect consumers from surprise medical bills, arbitration as payment mechanism H.R.2075,S.1013 School-Based Health Center Reauthorization Act - reauthorize school-based health centers S.1737 Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits H.R.748, S. 684 Middle Class Health Benefits Tax Repeal Act of 2019 - repeal the excise tax on high value employer-sponsored health care coverage, also known as the Cadillac Tax S.1935 Family Coverage Act - fix ACAs family glitch S. 1801 Affordable Medications Act - increase drug price transparency and affordability, spur innovation, and enhance competition S.455/ H.R.987 - MORE Health Education Act - funding for Federal Exchange outreach and educational activities H.R.3180, S. 1770 RISE (Resilience Investment, Support, and Expansion) from Trauma Act - improve the identification and support of children and families who experience trauma Draft legislation on patent evergreening Legislation to reauthorize the Patient-Centered Outcomes Research Institute (PCORI)

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE